# Immersion Corp: financial statements, quarterly

IMMR · Nasdaq · CIK 1058811 · [Technology](/sectors/technology.md) · fiscal year ends Apr 30

Pages: [Overview](/companies/immr.md) · [Financials](/companies/immr/financials.md) · [Filings](/companies/immr/filings.md) · [Insiders](/companies/immr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/immr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2025 (2024-03-31) | Q2 FY2025 (2024-06-30) | period not labelled (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | Q4 FY2025 (2025-04-30) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | Q4 FY2026 (2026-04-30) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [10.4 d](/filings/0001193125-26-102681.md) | [43.8](/filings/0001213900-24-040912.md) | [95.5](/filings/0001193125-26-102681.md) | [183](/filings/0001193125-26-124580.md) | [616](/filings/0001193125-26-153417.md) | [471](/filings/0001193125-26-201951.md) | [285 d](/filings/0001193125-26-316089.md) | [292](/filings/0001193125-26-389919.md) | [650](/filings/0001193125-26-153417.md) | [518](/filings/0001193125-26-201951.md) | [270 d](/filings/0001193125-26-316089.md) | [294](/filings/0001193125-26-389919.md) |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross profit | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [0.0 d](/filings/0001213900-24-021235.md) | [0.0](/filings/0001213900-24-040912.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [5.0 d](/filings/0001193125-26-102681.md) | [16.6](/filings/0001213900-24-040912.md) | [22.6](/filings/0001193125-26-102681.md) | [13.6](/filings/0001193125-26-124580.md) | [70.4](/filings/0001193125-26-153417.md) | [35.2](/filings/0001193125-26-201951.md) | [(1.2) d](/filings/0001193125-26-316089.md) | [(26.4)](/filings/0001193125-26-389919.md) | [40.1](/filings/0001193125-26-153417.md) | [5.0](/filings/0001193125-26-201951.md) | [7.2 d](/filings/0001193125-26-316089.md) | [(20.0)](/filings/0001193125-26-389919.md) |
| Interest expense | $m | [0.0 d](/filings/0001193125-26-102681.md) | not reported | [0.9](/filings/0001193125-26-102681.md) | [2.4](/filings/0001193125-26-124580.md) | [4.5](/filings/0001193125-26-153417.md) | [4.2](/filings/0001193125-26-201951.md) | [3.2 d](/filings/0001193125-26-316089.md) | [2.8](/filings/0001193125-26-389919.md) | [3.0](/filings/0001193125-26-153417.md) | [4.0](/filings/0001193125-26-201951.md) | [2.4 d](/filings/0001193125-26-316089.md) | [1.8](/filings/0001193125-26-389919.md) |
| Income tax | $m | [3.3 d](/filings/0001193125-26-102681.md) | [6.1](/filings/0001213900-24-040912.md) | [7.2](/filings/0001193125-26-102681.md) | [9.7](/filings/0001193125-26-124580.md) | [5.0](/filings/0001193125-26-153417.md) | [2.6](/filings/0001193125-26-201951.md) | [8.3 d](/filings/0001193125-26-316089.md) | [(7.7)](/filings/0001193125-26-389919.md) | [14.8](/filings/0001193125-26-153417.md) | [6.7](/filings/0001193125-26-201951.md) | [3.1 d](/filings/0001193125-26-316089.md) | [(2.1)](/filings/0001193125-26-389919.md) |
| Net income | $m | [16.0 d](/filings/0001193125-26-102681.md) | [18.7](/filings/0001213900-24-040912.md) | [26.4](/filings/0001193125-26-102681.md) | [27.1](/filings/0001193125-26-124580.md) | [30.8](/filings/0001193125-26-153417.md) | [24.1](/filings/0001193125-26-201951.md) | [(17.7) d](/filings/0001193125-26-316089.md) | [(0.9)](/filings/0001193125-26-389919.md) | [12.0](/filings/0001193125-26-153417.md) | [(10.3)](/filings/0001193125-26-201951.md) | [3.7 d](/filings/0001193125-26-316089.md) | [4.9](/filings/0001193125-26-389919.md) |
| Diluted EPS | $ per share | not reported | [0.59](/filings/0001213900-24-040912.md) | [0.81](/filings/0001193125-26-102681.md) | [0.83](/filings/0001193125-26-124580.md) | [0.93](/filings/0001193125-26-153417.md) | [0.73](/filings/0001193125-26-201951.md) | not reported | [(0.03)](/filings/0001193125-26-389919.md) | [0.36](/filings/0001193125-26-153417.md) | [(0.31)](/filings/0001193125-26-201951.md) | not reported | [0.17](/filings/0001193125-26-389919.md) |
| Basic EPS | $ per share | not reported | [0.60](/filings/0001213900-24-040912.md) | [0.83](/filings/0001193125-26-102681.md) | [0.85](/filings/0001193125-26-124580.md) | [0.95](/filings/0001193125-26-153417.md) | [0.74](/filings/0001193125-26-201951.md) | not reported | [(0.03)](/filings/0001193125-26-389919.md) | [0.37](/filings/0001193125-26-153417.md) | [(0.31)](/filings/0001193125-26-201951.md) | not reported | [0.17](/filings/0001193125-26-389919.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: not reported
- Gross profit: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2025 (2024-03-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-06-30) | period not labelled (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | FY2025 (2025-04-30) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | FY2026 (2026-04-30) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [91.1](/filings/0001213900-24-040912.md) | [85.5](/filings/0001193125-26-102681.md) | [35.8](/filings/0001213900-24-070789.md) | [57.7](/filings/0001193125-26-124580.md) | [80.5](/filings/0001193125-26-153417.md) | [77.7](/filings/0001193125-26-201951.md) | [72.6](/filings/0001193125-26-316089.md) | [90.1](/filings/0001193125-26-389919.md) | [127](/filings/0001193125-26-153417.md) | [130](/filings/0001193125-26-201951.md) | [138](/filings/0001193125-26-316089.md) | [175](/filings/0001193125-26-389919.md) |
| Current assets | $m | [194](/filings/0001213900-24-040912.md) | [191](/filings/0001213900-25-022972.md) | [676](/filings/0001193125-26-102681.md) | not reported | [834](/filings/0001193125-26-102681.md) | [919](/filings/0001193125-26-102681.md) | [632](/filings/0001193125-26-316089.md) | [797](/filings/0001193125-26-124580.md) | [934](/filings/0001193125-26-153417.md) | [1,013](/filings/0001193125-26-201951.md) | [675](/filings/0001193125-26-389919.md) | [811](/filings/0001193125-26-389919.md) |
| Total assets | $m | [245](/filings/0001213900-24-040912.md) | [247](/filings/0001213900-25-022972.md) | [1,234](/filings/0001193125-26-102681.md) | not reported | [1,364](/filings/0001193125-26-102681.md) | [1,438](/filings/0001193125-26-102681.md) | [1,102](/filings/0001193125-26-316089.md) | [1,262](/filings/0001193125-26-124580.md) | [1,377](/filings/0001193125-26-153417.md) | [1,433](/filings/0001193125-26-201951.md) | [1,052](/filings/0001193125-26-389919.md) | [1,177](/filings/0001193125-26-389919.md) |
| Current liabilities | $m | [30.1](/filings/0001213900-24-040912.md) | [30.2](/filings/0001213900-25-022972.md) | [438](/filings/0001213900-24-070789.md) | not reported | [531](/filings/0001193125-26-102681.md) | [543](/filings/0001193125-26-102681.md) | [266](/filings/0001193125-26-316089.md) | [358](/filings/0001193125-26-124580.md) | [496](/filings/0001193125-26-153417.md) | [554](/filings/0001193125-26-201951.md) | [293](/filings/0001193125-26-389919.md) | [379](/filings/0001193125-26-389919.md) |
| Total liabilities | $m | [43.2](/filings/0001213900-24-040912.md) | [45.3](/filings/0001213900-25-022972.md) | [820](/filings/0001193125-26-102681.md) | not reported | [877](/filings/0001193125-26-102681.md) | [850](/filings/0001193125-26-102681.md) | [544](/filings/0001193125-26-316089.md) | [716](/filings/0001193125-26-124580.md) | [803](/filings/0001193125-26-153417.md) | [871](/filings/0001193125-26-201951.md) | [485](/filings/0001193125-26-389919.md) | [617](/filings/0001193125-26-389919.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | [103](/filings/0001193125-26-316089.md) | not reported | not reported | not reported | [71.0](/filings/0001193125-26-316089.md) | not reported |
| Short-term borrowings | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0](/filings/0001193125-26-316089.md) | not reported | not reported | not reported | [0.0](/filings/0001193125-26-316089.md) | not reported |
| Shareholders' equity | $m | [201](/filings/0001213900-24-040912.md) | [201](/filings/0001213900-25-022972.md) | [273](/filings/0001193125-26-102681.md) | [407](/filings/0001193125-26-153417.md) | [306](/filings/0001193125-26-102681.md) | [318](/filings/0001193125-26-102681.md) | [298](/filings/0001193125-26-316089.md) | [296](/filings/0001193125-26-124580.md) | [307](/filings/0001193125-26-153417.md) | [295](/filings/0001193125-26-201951.md) | [297](/filings/0001193125-26-389919.md) | [299](/filings/0001193125-26-389919.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity, us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2025 (2024-03-31) | Q2 FY2025 (2024-06-30) | period not labelled (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | Q4 FY2025 (2025-04-30) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | Q4 FY2026 (2026-04-30) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [7.8 d](/filings/0001193125-26-102681.md) | [29.9](/filings/0001213900-24-040912.md) | [(85.9) d](/filings/0001193125-26-102681.md) | [(114)](/filings/0001193125-26-124580.md) | [50.4 d](/filings/0001193125-26-153417.md) | [(43.7) d](/filings/0001193125-26-201951.md) | [50.1 d](/filings/0001193125-26-316089.md) | [(61.7)](/filings/0001193125-26-389919.md) | [70.6 d](/filings/0001193125-26-153417.md) | [(33.8) d](/filings/0001193125-26-201951.md) | [83.8 d](/filings/0001193125-26-316089.md) | [(43.6)](/filings/0001193125-26-389919.md) |
| Capital expenditure | $m | [(0.0) d](/filings/0001193125-26-102681.md) | not reported | not reported | [2.8](/filings/0001193125-26-124580.md) | [2.8 d](/filings/0001193125-26-153417.md) | [2.5 d](/filings/0001193125-26-201951.md) | [3.1 d](/filings/0001193125-26-316089.md) | [3.7](/filings/0001193125-26-389919.md) | [4.3 d](/filings/0001193125-26-153417.md) | [3.7 d](/filings/0001193125-26-201951.md) | [4.4 d](/filings/0001193125-26-316089.md) | [3.5](/filings/0001193125-26-389919.md) |
| Dividends paid | $m | [1.0 d](/filings/0001193125-26-102681.md) | [1.5](/filings/0001213900-24-040912.md) | [1.5 d](/filings/0001193125-26-102681.md) | [1.5](/filings/0001193125-26-124580.md) | [1.5 d](/filings/0001193125-26-153417.md) | [8.3 d](/filings/0001193125-26-201951.md) | [1.5 d](/filings/0001193125-26-316089.md) | [0.0](/filings/0001193125-26-389919.md) | [3.0 d](/filings/0001193125-26-153417.md) | [2.5 d](/filings/0001193125-26-201951.md) | [2.5 d](/filings/0001193125-26-316089.md) | [2.5](/filings/0001193125-26-389919.md) |
| Share repurchases | $m | [2.1 d](/filings/0001193125-26-102681.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2025 (2024-03-31) | Q2 FY2025 (2024-06-30) | period not labelled (2024-07-31) | Q2 FY2025 (2024-10-31) | Q3 FY2025 (2025-01-31) | Q1 FY2026 (2025-07-31) | Q2 FY2026 (2025-10-31) | Q3 FY2026 (2026-01-31) | Q1 FY2027 (2026-07-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [33.1](/filings/0001213900-24-095967.md) | [32.8](/filings/0001213900-24-109054.md) | [32.8](/filings/0001213900-25-022972.md) | [31.4](/filings/0001213900-24-040912.md) | [0.0](/filings/0001193125-26-102681.md) | [32.7](/filings/0001193125-26-124580.md) | [32.9](/filings/0001193125-26-153417.md) | [33.1](/filings/0001193125-26-201951.md) | [32.6](/filings/0001193125-26-389919.md) | [33.2](/filings/0001193125-26-153417.md) | [32.9](/filings/0001193125-26-201951.md) | [33.3](/filings/0001193125-26-389919.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 33,206,041 at 2026-09-08, from the cover of the [10-Q filed 2026-09-14](/filings/0001193125-26-389919.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:32 ET. No prices; not investment advice.